Comparison
While FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38, KPV is investigated as an anti-inflammatory and barrier-protective agent in skin and mucosal models, reducing pro-inflammatory cytokines and promoting tissue repair684.
While FOXO4-DRI works as a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38, KPV is the C-terminal Lys-Pro-Val tripeptide fragment of α-MSH, which exerts potent anti-inflammatory effects largely via inhibition of NF-κB signaling and modulation of cytokine expression, with many actions independent of classical melanocortin receptor activation684.
FOXO4-DRI is amino acids long, whereas KPV is longer as it has a length of 3 amino acids. FOXO4-DRI is made up of a sequence of sequence data not available in the current dataset. KPV is made up of a sequence of Lysine, Proline, Valine.
FOXO4-DRI
Intracellular target is the FOXO4–p53 protein–protein interaction interface; it does not signal via a traditional cell-surface receptor38
KPV
FOXO4-DRI
FOXO4
KPV
POMC
No related articles are linked to these peptides yet.